Chroma Medicine and Nvelop Therapeutics Merge to Form nChroma Bio

NLS Pharmaceutics Merges with Kadimastem to Form NewCelX

June 27, 2025

Biotechnology

NLS Pharmaceutics Ltd. completed a $3.0 million equity financing to support its pending merger with Kadimastem Ltd.; the transaction closed and the combined company was re-named NewCelX Ltd. The deal brings together NLS's CNS-focused pipeline and Kadimastem's cell therapy programs (AstroRx and IsletRx) to advance clinical development for ALS, diabetes and other regenerative-medicine indications.

ARCHIMED Acquires and Merges Symbio and Proinnovera to Form Symbio Proinnovera

November 17, 2023

Healthcare Services

ARCHIMED has acquired US-based Symbio and Germany-based Proinnovera in an all-equity deal and merged them to create Symbio Proinnovera, a specialized dermatology-focused CRO. The combined group will offer end-to-end dermatology consulting, formulation, testing and clinical research across North America and Europe, with founders rolling equity into the new platform and ARCHIMED-appointed operating partners joining the board to drive growth and further acquisitions.

Catalyst Clinical Research Merges with Ce3, Inc.

August 5, 2020

Healthcare Services

Catalyst Clinical Research, a NovaQuest-backed CRO headquartered in Wilmington, North Carolina, has merged with Ce3, Inc., an early-phase oncology-focused CRO based in Clinton, Connecticut. The transaction combines Ce3's 15+ years of oncology expertise with Catalyst's broader clinical development and technology capabilities to create a next-generation oncology-focused CRO (add-on to Catalyst's NovaQuest-backed platform).

Dipharma Inc. Merges Kalexsyn, Inc. into Parent to Complete Integration

January 4, 2022

Pharmaceuticals

Dipharma Inc., part of the Dipharma Group, has merged Kalexsyn, Inc. (a Michigan corporation acquired in 2018) into its 100% owner, Dipharma Inc., effective January 1, 2022. The merger completes Kalexsyn's formal integration and strengthens Dipharma's U.S. cGMP and CRO capabilities in Kalamazoo to support services from discovery through commercialization.

Chroma Color Corporation Acquires Epolin Chemicals

June 3, 2020

Manufacturing

Chroma Color Corporation, a portfolio company of Arsenal Capital Partners, has acquired Epolin Chemicals LLC, a developer and manufacturer of near-infrared (NIR) absorbing dyes and thermoplastic compounds. The acquisition expands Chroma Color’s product portfolio and technical capabilities in NIR dye technology while Epolin will operate as an independent subsidiary to enable cross-selling and continued investment in R&D.

BioCina and NovaCina Merge to Create Integrated Global CDMO

January 13, 2025

Pharmaceuticals

BioCina and NovaCina announced a strategic merger that will combine BioCina's process development and manufacturing capabilities in Adelaide with NovaCina's sterile fill-finish facility in Perth. The combined company will retain the BioCina name and provide an end-to-end CDMO offering for small molecules and biopharmaceuticals, backed by parent Bridgewest Group.